Alector Inc

NASDAQ:ALEC   3:55:53 PM EDT
13.28
+0.05 (+0.38%)
Other Pre-Announcement

Alector On Track To Initiate Phase 2 Study For AL002 In Alzheimer's Disease In 2020

Published: 11/10/2020 21:29 GMT
Alector Inc (ALEC) - Alector Reports Third Quarter 2020 Financial Results and Provides Corporate Update.
Alector Inc - on Track to Initiate Phase 2 Study for Al002 in Alzheimer's Disease in 2020.
Alector Inc - Qtrly Loss per Share $0.67.
Alector Inc - Cash, Cash Equivalents, and Marketable Securities Were $461.7 Million As of September 30, 2020.
Alector - Believes Cash, Investments As of Sept 30, to Be Sufficient to Fund Anticipated Operations Through 2022.